| Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage A Fluckiger, R Daillère, M Sassi, BS Sixt, P Liu, F Loos, C Richard, ... Science 369 (6506), 936-942, 2020 | 298 | 2020 |
| Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer Z Sztupinszki, M Diossy, M Krzystanek, L Reiniger, I Csabai, F Favero, ... NPJ breast cancer 4 (1), 16, 2018 | 228 | 2018 |
| Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations Z Sztupinszki, M Diossy, M Krzystanek, J Borcsok, MM Pomerantz, V Tisza, ... Clinical Cancer Research 26 (11), 2673-2680, 2020 | 90 | 2020 |
| Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors M Diossy, L Reiniger, Z Sztupinszki, M Krzystanek, KM Timms, C Neff, ... Annals of Oncology 29 (9), 1948-1954, 2018 | 76 | 2018 |
| A comprehensive overview of targeted therapy in metastatic renal cell carcinoma Z Mihály, Z Sztupinszki, P Surowiak, B Gyorffy Current cancer drug targets 12 (7), 857-872, 2012 | 70 | 2012 |
| CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer T Tsujino, T Takai, K Hinohara, F Gui, T Tsutsumi, X Bai, C Miao, C Feng, ... Nature Communications 14 (1), 252, 2023 | 58 | 2023 |
| Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers NJ Birkbak, Y Li, S Pathania, A Greene-Colozzi, M Dreze, ... Annals of Oncology 29 (4), 903-909, 2018 | 53 | 2018 |
| The CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer AM Szász, Q Li, AC Eklund, Z Sztupinszki, A Rowan, AM Tőkés, B Székely, ... PloS one 8 (2), e56707, 2013 | 43 | 2013 |
| A TLR3 ligand reestablishes chemotherapeutic responses in the context of FPR1 deficiency J Le Naour, P Liu, L Zhao, S Adjemian, Z Sztupinszki, J Taieb, C Mulot, ... Cancer Discovery 11 (2), 408-423, 2021 | 42 | 2021 |
| Altered mucosal expression of microRNAs in pediatric patients with inflammatory bowel disease NJ Béres, Z Kiss, Z Sztupinszki, G Lendvai, A Arató, E Sziksz, Á Vannay, ... Digestive and Liver Disease 49 (4), 378-387, 2017 | 36 | 2017 |
| Identification of a synthetic lethal relationship between nucleotide excision repair deficiency and irofulven sensitivity in urothelial cancer J Börcsök, Z Sztupinszki, R Bekele, SP Gao, M Diossy, AS Samant, ... Clinical Cancer Research 27 (7), 2011-2022, 2021 | 32 | 2021 |
| RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer C Miao, T Tsujino, T Takai, F Gui, T Tsutsumi, Z Sztupinszki, Z Wang, ... Science Advances 8 (7), eabl9794, 2022 | 31 | 2022 |
| Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines Z Pénzváltó, B Tegze, AM Szász, Z Sztupinszki, I Likó, A Szendrői, ... PloS one 8 (3), e59503, 2013 | 31 | 2013 |
| Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models Z Sztupinszki, B Győrffy Scientific Reports 6 (1), 37169, 2016 | 30 | 2016 |
| ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer I Mota, E Patrucco, C Mastini, NR Mahadevan, TC Thai, E Bergaggio, ... Nature Cancer 4 (7), 1016-1035, 2023 | 29 | 2023 |
| Circulating protein biomarkers for use in pancreatic ductal adenocarcinoma identification SC Lindgaard, Z Sztupinszki, E Maag, IM Chen, AZ Johansen, BV Jensen, ... Clinical Cancer Research 27 (9), 2592-2603, 2021 | 28 | 2021 |
| RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics RT Bekele, AS Samant, AH Nassar, J So, EP Garcia, CR Curran, ... The Journal of Clinical Investigation 131 (22), 2021 | 25 | 2021 |
| Comparative assessment of diagnostic homologous recombination deficiency–associated mutational signatures in ovarian cancer Z Sztupinszki, M Diossy, J Borcsok, A Prosz, N Cornelius, MK Kjeldsen, ... Clinical Cancer Research 27 (20), 5681-5687, 2021 | 25 | 2021 |
| A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures M Diossy, Z Sztupinszki, J Borcsok, M Krzystanek, V Tisza, S Spisak, ... NPJ Precision Oncology 5 (1), 55, 2021 | 25 | 2021 |
| PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer KM Dillon, RT Bekele, Z Sztupinszki, T Hanlon, S Rafiei, Z Szallasi, ... NPJ Precision Oncology 6 (1), 49, 2022 | 24 | 2022 |